ARMP Stock Price, Armata Pharmaceuticals Quote, Chart

Market Summary

USD2.55-0.10

Delayed

-3.77%

ARMP Stock Price

View Fullscreen

ARMP RSI Chart

ARMP Valuation

Market Cap

92.2M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

19.62

EV/EBITDA

30.46

Price/Free Cashflow

-1.97

ARMP Price/Sales (Trailing)

ARMP Profitability

EBT Margin

-1.47%

Return on Equity

140.82%

Return on Assets

-66.12%

Free Cashflow Yield

-50.79%

ARMP Fundamentals

ARMP Revenue

Revenue (TTM)

4.7M

Rev. Growth (Yr)

21.36%

Rev. Growth (Qtr)

-36.78%

ARMP Earnings

Earnings (TTM)

-79.6M

Earnings Growth (Yr)

-72.68%

Earnings Growth (Qtr)

-26.07%

Breaking Down ARMP Revenue

Last 7 days

-17.5%

Last 30 days

2%

Last 90 days

-13.3%

Trailing 12 Months

96.2%

How does ARMP drawdown profile look like?

ARMP Financial Health

Current Ratio

0.38

Debt/Equity

-1.04

Debt/Cashflow

-0.69

ARMP Investor Care

Shares Dilution (1Y)

0.03%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.7M	0	0	0
2023	5.1M	4.2M	4.1M	4.5M
2022	4.6M	5.4M	5.4M	5.5M
2021	1.7M	2.6M	3.6M	4.5M
2020	0	351.0K	587.0K	823.0K
2017	183.0K	108.0K	117.0K	115.0K
2016	479.0K	480.0K	366.0K	260.0K
2015	407.0K	408.0K	448.0K	475.0K
2014	163.0K	245.0K	327.0K	409.0K
2013	0	0	0	81.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Armata Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	birx deborah	acquired	-	-	60,000	chief executive officer
Mar 14, 2024	rychlik richard	acquired	-	-	10,000	corporate controller and pfo
Dec 21, 2023	birx deborah	acquired	-	-	200,000	chief executive officer
Mar 31, 2022	innoviva, inc.	bought	26,926,000	5.00	5,385,210	-
Feb 09, 2022	innoviva, inc.	bought	18,074,000	5.00	3,614,790	-
Oct 29, 2021	innoviva, inc.	bought	4,000,000	3.3	1,212,120	-
Mar 17, 2021	innoviva, inc.	bought	13,929,300	3.25	4,285,940	-
Jan 26, 2021	innoviva, inc.	bought	6,070,710	3.25	1,867,910	-
Mar 27, 2020	innoviva, inc.	bought	22,149,700	2.87	7,717,660	-

Which funds bought or sold ARMP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	37,882	168,454	-%
May 15, 2024	MORGAN STANLEY	added	21,200	1,774	1,780	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	0.34	605,525	2,661,150	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-49.6	-3,816	7,093	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	reduced	-3.01	11,029	54,925	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	537	2,387	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	103,759	461,397	0.01%
May 15, 2024	Royal Bank of Canada	reduced	-90.78	-1,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	75,094	75,094	-%
May 14, 2024	EDGEWOOD MANAGEMENT LLC	unchanged	-	94,000	418,000	-%

Are Funds Buying or Selling ARMP?

Are funds buying ARMP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARMP

No. of Funds

Unveiling Armata Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 04, 2024	innoviva, inc.	85.3%	64,178,259	SC 13D/A
Jul 11, 2023	innoviva, inc.	85.3%	64,178,259	SC 13D/A
Jan 10, 2023	innoviva, inc.	85.3%	64,178,259	SC 13D/A
Apr 01, 2022	innoviva, inc.	80.1%	44,441,416	SC 13D/A
Feb 11, 2022	innoviva, inc.	76.7%	36,363,604	SC 13D/A
Nov 01, 2021	innoviva, inc.	73.8%	30,941,416	SC 13D/A
Apr 05, 2021	innoviva, inc.	-	0	SC 13D/A
Mar 17, 2021	innoviva, inc.	74.7%	29,729,294	SC 13D/A
Jan 27, 2021	innoviva, inc.	68%	21,157,424	SC 13D/A
Mar 31, 2020	innoviva, inc.	63.7%	17,421,600	SC 13D/A

Recent SEC filings of Armata Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Mar 22, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Armata Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Armata Pharmaceuticals Inc News

Latest updates

Armata Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4
Revenue	-36.8%	966,000	1,528,000	1,225,000	980,000	796,000	1,051,000	1,338,000	1,883,000	1,236,000	989,000	1,251,000	1,168,000	1,066,000	804,500	543,000	281,500	20,000	38,000	28,000	29,000	22,000
Operating Expenses	0.8%	11,194,000	11,107,000	11,561,000	10,609,000	12,142,000	11,379,000	9,961,000	11,103,000	10,011,000	7,037,000	7,394,000	7,364,000	6,501,000	6,957,000	5,911,000	4,621,000	-	-	-	-	-
S&GA Expenses	-100.0%	-	3,178,500	3,583,000	2,350,000	2,538,000	1,810,000	1,561,000	2,083,000	1,983,000	2,223,000	1,768,000	2,139,000	2,151,000	1,977,000	1,845,000	1,973,000	-	-	-	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92,000	292,000	138,000	10,958,000	-829,000	1,130,000	1,490,000	802,000
EBITDA Margin	-3.6%	0.75	0.78	0.21	0.21	0.17	0.15	-2.92	-2.95	-3.38	-3.49	-4.34	-5.78	-	-	-	-	-	-	-	-	-
Interest Expenses	25.5%	1,820,000	1,450,000	1,176,000	-	-	-	-	-	-	-	2,000	-	62,000	177,000	150,000	142,000	-	-	-	7,000	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,352,000	-779,000	-7,763,000	-	-10,056,000
EBT Margin	3.6%	-0.01	-0.02	-0.01	-0.01	-0.01	-0.01	-3.09	-3.14	-3.63	-3.76	-4.73	-6.36	-	-	-	-	-	-	-	-	-
Net Income	-26.1%	-25,021,000	-19,847,000	-31,161,000	-3,547,000	-14,490,000	-10,314,000	-8,614,000	-9,215,000	-8,774,000	-6,047,000	-5,419,000	-6,194,000	-5,495,000	-6,624,000	-5,769,000	-4,710,000	-	-	-	-	-
Net Income Margin	-11.1%	-16.93	-15.25	-14.69	-8.88	-8.41	-6.70	-6.00	-5.50	-5.69	-5.18	-6.66	-9.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-3.1%	-10,834,000	-10,506,000	-13,199,000	-12,282,000	-19,580,000	-10,030,000	-11,627,000	-9,284,000	-3,751,000	-8,826,000	-5,546,000	-4,734,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	22.4%	120	98.00	113	101	109	96.00	93.00	101	108	70.00	43.00	48.00	53.00	40.00	46.00	49.00	44.00	25.00	29.00	35.00	10.00
Current Assets	117.8%	42.00	19.00	37.00	27.00	39.00	27.00	33.00	41.00	49.00	15.00	14.00	20.00	24.00	11.00	17.00	21.00	26.00	7.00	10.00	14.00	6.00
Cash Equivalents	220.5%	43.00	14.00	24.00	12.00	25.00	15.00	25.00	37.00	46.00	11.00	12.00	18.00	22.00	11.00	16.00	20.00	24.00	7.00	9.00	13.00	6.00
Net PPE	1.1%	13.00	13.00	9.00	9.00	5.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	0.00
Goodwill	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-
Liabilities	35.6%	177	130	125	82.00	86.00	60.00	47.00	48.00	46.00	44.00	19.00	20.00	19.00	21.00	21.00	20.00	11.00	11.00	11.00	12.00	5.00
Current Liabilities	568.5%	110	16.00	22.00	52.00	51.00	25.00	7.00	7.00	6.00	5.00	5.00	6.00	5.00	7.00	7.00	5.00	6.00	5.00	5.00	6.00	4.00
Long Term Debt	-100.0%	-	59.00	50.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	59.00	50.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-76.2%	-56.51	-32.06	-	19.00	22.00	36.00	46.00	53.00	62.00	25.00	24.00	29.00	34.00	19.00	25.00	30.00	33.00	15.00	18.00	23.00	4.00
Retained Earnings	-8.1%	-333	-308	-289	-257	-254	-239	-229	-220	-211	-202	-196	-191	-185	-179	-173	-167	-162	-157	-152	-145	-409
Additional Paid-In Capital	0.2%	277	276	276	277	276	275	275	274	273	228	220	220	219	198	198	197	196	172	171	169	415
Accumulated Depreciation	2.7%	12.00	12.00	-	-	-	11.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.0%	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	29.00	27.00	23.00	23.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	13.00	-	-	-	42.00	-	-	-	39.00	-	-	-	38.00	-	-	-	39.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-30.6%	-10,584	-8,106	-9,687	-12,060	-17,570	-10,485	-10,333	-8,148	-3,515	-8,598	-4,964	-4,538	-5,475	-6,302	-3,880	-3,856	-4,232	-2,729	-4,567	-5,827	-2,459
Share Based Compensation	176.7%	534	193	-373	261	857	817	846	949	493	664	469	907	842	862	663	906	1,044	1,047	2,499	626	99.00
Cashflow From Investing	89.5%	-250	-2,390	-3,512	-222	-2,010	455	-1,294	-1,136	-236	-228	-582	-196	-298	-366	-81.00	-273	-104	72.00	65.00	2,882	-142
Cashflow From Financing	81334.9%	34,931	-43.00	24,805	-368	29,594	-500	31.00	-146	44,631	7,038	86.00	-185	18,579	432	60.00	306	22,412	-	-	9,975	-1,000

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARMP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations
Grant revenue	$ 966	$ 796
Operating expenses
Research and development	8,016	9,604
General and administrative	3,178	2,538
Total operating expenses	11,194	12,142
Loss from operations	(10,228)	(11,346)
Other income (expense)
Interest income	52	18
Interest expense	(1,820)
Change in fair value of convertible debt	(13,025)	(3,162)
Total other (expense) income, net	(14,793)	(3,144)
Net loss	$ (25,021)	$ (14,490)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.69)	$ (0.40)
Net loss per share, diluted (in dollars per share)	$ (0.69)	$ (0.40)
Weighted average shares outstanding, basic (in shares)	36,124,980	36,045,040
Weighted average shares outstanding, diluted (in shares)	36,124,980	36,045,040

ARMP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash	$ 37,860	$ 13,523
Prepaid expenses and other current assets	2,143	2,265
Other receivables	1,714	3,363
Total current assets	41,717	19,151
Restricted cash	5,480	5,720
Property and equipment, net	12,700	12,559
Operating lease right-of-use asset	44,243	44,717
In-process research and development	10,256	10,256
Goodwill	3,490	3,490
Other assets	2,470	2,470
Total assets	120,356	98,363
Current liabilities
Accounts payable and accrued liabilities	4,610	5,689
Accrued compensation	948	768
Convertible debt	71,658
Term debt, current	25,010
Current portion of operating lease liabilities	7,497	9,481
Other current liabilities	322	523
Total current liabilities	110,045	16,461
Operating lease liabilities, net of current portion	28,376	28,583
Convertible debt		58,633
Term debt non-current	35,368	23,674
Deferred tax liability	3,077	3,077
Total liabilities	176,866	130,428
Commitments and contingencies (Note 12)
Stockholders' deficit
Common stock, $0.01 par value; 217,000,000 shares authorized; 36,132,117 and 36,122,932 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	361	361
Additional paid-in capital	276,969	276,393
Accumulated deficit	(333,840)	(308,819)
Total stockholders' deficit	(56,510)	(32,065)
Total liabilities and stockholders' deficit	$ 120,356	$ 98,363

About Armata Pharmaceuticals Inc

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

CEO	Dr. Deborah L. Birx M.D.
WEBSITE	armatapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	72

Armata Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Armata Pharmaceuticals Inc? What does ARMP stand for in stocks?

ARMP is the stock ticker symbol of Armata Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Armata Pharmaceuticals Inc (ARMP)?

As of Fri May 17 2024, market cap of Armata Pharmaceuticals Inc is 92.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARMP stock?

You can check ARMP's fair value in chart for subscribers.

What is the fair value of ARMP stock?

You can check ARMP's fair value in chart for subscribers. The fair value of Armata Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Armata Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARMP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Armata Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARMP is over valued or under valued. Whether Armata Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Armata Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARMP.

What is Armata Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ARMP's PE ratio (Price to Earnings) is -1.16 and Price to Sales (PS) ratio is 19.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARMP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Armata Pharmaceuticals Inc's stock?

In the past 10 years, Armata Pharmaceuticals Inc has provided -0.27 (multiply by 100 for percentage) rate of return.